{"meta":{"query_hash":"9373f12a084b","filters":{"venue":"touchREVIEWS in Neurology"},"cohort_total":15,"direct_labels_cover":0,"predictions_cover":15,"exported":15,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/9373f12a084b","api":"https://metacan.xera.ac/api/v1/cohort?venue=touchREVIEWS+in+Neurology"},"results":[{"id":"W2482237976","doi":"10.17925/usn.2015.11.01.19","title":"Physical Activity in Pediatric Multiple Sclerosis—Can Lifestyle Factors Affect Disease Outcomes?","year":2015,"lang":"en","type":"article","venue":"touchREVIEWS in Neurology","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"Hospital for Sick Children; Multiple Sclerosis Society; Multiple Sclerosis Society of Canada; Canadian Institutes of Health Research; Multiple Sclerosis Scientific Research Foundation; Public Health Agency; Dairy Farmers of Ontario; Public Health Agency of Canada; EMD Serono; National Multiple Sclerosis Society","keywords":"Medicine; Affect (linguistics); Multiple sclerosis; Depression (economics); Disease; Psychological intervention; Neuroinflammation; Population; Cognition; Physical activity; Physical therapy; Physical medicine and rehabilitation; Clinical psychology; Gerontology; Psychiatry; Psychology; Environmental health; Internal medicine","score_opus":0.1576437093915405,"score_gpt":0.36931030302408674,"score_spread":0.21166659363254625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2482237976","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993236,0.0010325686,0.00000519824,0.0034991254,0.00025360627,0.0016640325,0.000022745307,0.00007289259,0.00021381877],"genre_scores_gemma":[0.99544746,0.0031459264,0.000043982178,0.0007014117,0.00026846828,0.00029513615,0.000012931844,0.000043814427,0.00004086377],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99660826,0.0009376382,0.00041169117,0.0007241968,0.0005270685,0.0007911461],"domain_scores_gemma":[0.9972207,0.0012298587,0.00014138775,0.00070120505,0.0000738698,0.0006329659],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006802141,0.0003906676,0.0012841574,0.00041732506,0.000044926775,0.000014320693,0.00027560376,0.00011620911,0.000020990106],"category_scores_gemma":[0.007872079,0.0002948629,0.00025378252,0.00073078496,0.00017477648,0.00012271723,0.00034639923,0.00089904957,0.0000989317],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004875723,0.0011969,0.99193937,0.00024455567,0.000012715792,0.000110916335,0.00025820953,0.000039256163,0.00028943276,0.000007332737,0.00077311584,0.0046406244],"study_design_scores_gemma":[0.003442174,0.0005195274,0.9935862,0.00004947917,0.000047891248,0.0000019962886,0.000007972253,0.0009668261,0.00006950045,0.000020812327,0.0010817987,0.00020586046],"about_ca_topic_score_codex":0.00032804525,"about_ca_topic_score_gemma":0.0007103606,"teacher_disagreement_score":0.0071918643,"about_ca_system_score_codex":0.00013591284,"about_ca_system_score_gemma":0.0002040151,"threshold_uncertainty_score":0.99995035},"labels":[],"label_agreement":null},{"id":"W2487736606","doi":"10.17925/usn.2015.11.01.47","title":"Chronic Inflammatory Demyelinating Polyneuropathy in Diabetes Patients","year":2015,"lang":"en","type":"article","venue":"touchREVIEWS in Neurology","topic":"Peripheral Neuropathies and Disorders","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital; University of Toronto; University Health Network","funders":"Eisai; Grifols; CSL Behring; Pfizer; Eli Lilly and Company","keywords":"Medicine; Chronic inflammatory demyelinating polyneuropathy; Polyneuropathy; Weakness; Diabetes mellitus; Polyradiculoneuropathy; Pathophysiology; Internal medicine; Nerve conduction velocity; Gastroenterology; Surgery; Pediatrics; Guillain-Barre syndrome; Immunology; Antibody; Endocrinology","score_opus":0.01984212578548503,"score_gpt":0.2651941285470983,"score_spread":0.24535200276161326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2487736606","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98881364,0.007195207,0.0000015355168,0.0011476107,0.00045881822,0.00060313905,0.0000013928958,0.000047241105,0.001731415],"genre_scores_gemma":[0.9910426,0.0012041536,0.00003195647,0.0074035265,0.00015828434,0.00007528683,0.000008606986,0.000038299673,0.000037284302],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99779165,0.00039425428,0.0006401895,0.00041209834,0.00019084703,0.0005709644],"domain_scores_gemma":[0.999246,0.00008224055,0.0001314935,0.0003283719,0.00005521258,0.00015669479],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044839238,0.00022062025,0.0005527468,0.00021599459,0.000020550393,0.0000069237694,0.00015882465,0.000114473965,0.00004283107],"category_scores_gemma":[0.0010356295,0.00019796606,0.0000776692,0.0003635335,0.000092061535,0.00009909567,0.00012895,0.00049130636,0.00006173823],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009338243,0.00014994806,0.9576994,0.00017744303,0.0000024832718,0.00018145576,0.0001763496,0.000078082325,0.0002676509,0.00004834758,0.00080895965,0.040316477],"study_design_scores_gemma":[0.0077145398,0.0030557746,0.75054544,0.00022761105,0.000024536746,0.00002520723,0.000025187199,0.0020776575,0.00006003013,0.0003904083,0.2354706,0.00038304707],"about_ca_topic_score_codex":0.000026063137,"about_ca_topic_score_gemma":0.00031511195,"teacher_disagreement_score":0.23466162,"about_ca_system_score_codex":0.0000762393,"about_ca_system_score_gemma":0.00013858025,"threshold_uncertainty_score":0.80728215},"labels":[],"label_agreement":null},{"id":"W2490618669","doi":"10.17925/usn.2014.10.02.90","title":"Magnetic Resonance Imaging and Dopamine Transporter Single Photon Emission Tomography in Parkinson’s Disease—When Should We Use Them?","year":2014,"lang":"en","type":"article","venue":"touchREVIEWS in Neurology","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Movement Disorders","funders":"","keywords":"Medicine; Magnetic resonance imaging; Dopamine transporter; Parkinson's disease; Disease; Medical diagnosis; Dopamine; Radiology; Pathology; Internal medicine; Dopaminergic","score_opus":0.03341976575299417,"score_gpt":0.2601324053259612,"score_spread":0.22671263957296706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2490618669","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94428414,0.05117721,0.000060344206,0.0029495612,0.00014002543,0.00092161645,0.000020065474,0.000052263134,0.000394755],"genre_scores_gemma":[0.98311377,0.012318525,0.0005384421,0.0036611964,0.00005475354,0.00015560177,0.000026162701,0.000041549032,0.00008997916],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997937,0.00026392037,0.00047865824,0.0006970464,0.00018516574,0.00043816748],"domain_scores_gemma":[0.99901736,0.000117470016,0.00009185689,0.0004702793,0.000020710346,0.00028230838],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00024525542,0.00031462396,0.0006314937,0.0002312622,0.000037321523,0.000017771992,0.00011101624,0.00008592032,0.00019284524],"category_scores_gemma":[0.00008516985,0.00025303263,0.000121551064,0.00023222041,0.00009824575,0.000116145784,0.000040907158,0.00026726458,0.0000120012455],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00068602193,0.00053195516,0.80235714,0.00019577016,0.0000041394674,0.00081107044,0.00007696452,3.5409644e-7,0.0010573342,0.00006176746,0.00020257311,0.19401489],"study_design_scores_gemma":[0.0022339025,0.0002946764,0.59146905,0.00033590567,0.00008628479,0.000053245232,0.0000018461401,0.00051506085,0.00017500146,0.0013900753,0.4032857,0.00015922548],"about_ca_topic_score_codex":0.000065756365,"about_ca_topic_score_gemma":0.000053630338,"teacher_disagreement_score":0.40308315,"about_ca_system_score_codex":0.000024980112,"about_ca_system_score_gemma":0.000023882792,"threshold_uncertainty_score":0.9999922},"labels":[],"label_agreement":null},{"id":"W2492235344","doi":"10.17925/usn.2014.10.02.2","title":"Pharmacologic Decision-making in the Treatment of Focal Epilepsy—A Critical Comparison of Antiepileptic Drugs","year":2014,"lang":"en","type":"article","venue":"touchREVIEWS in Neurology","topic":"Epilepsy research and treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Deutsche Forschungsgemeinschaft; Eisai; Valeant Pharmaceuticals International; Pfizer; Upsher-Smith; GlaxoSmithKline; Epilepsy Foundation","keywords":"Medicine; Polypharmacy; Epilepsy; Tolerability; Intensive care medicine; Antiepileptic drug; Dosing; Concomitant; Drug; Clinical trial; Psychiatry; Pharmacology; Adverse effect; Surgery; Internal medicine","score_opus":0.050738225822317365,"score_gpt":0.43350169861724114,"score_spread":0.3827634727949238,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2492235344","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9867243,0.00835003,0.0001373081,0.0019711975,0.00015361291,0.0010768941,0.0000039356787,0.000009297724,0.0015734048],"genre_scores_gemma":[0.99274784,0.0055066673,0.00069345685,0.0008239137,0.000067551715,0.00014032521,0.00000449656,0.000012150385,0.0000036105994],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99697226,0.0010325543,0.00093303877,0.00033787705,0.00030714672,0.00041710795],"domain_scores_gemma":[0.99474245,0.0045175436,0.00014179974,0.00046273204,0.00005825658,0.00007719085],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008109944,0.00019814676,0.0011552831,0.0001935978,0.000028303542,0.000003802049,0.00021795547,0.00011111639,0.0002065541],"category_scores_gemma":[0.0008861482,0.00011542627,0.00019435503,0.00037275534,0.00032873056,0.000028942133,0.00003856826,0.00029522614,0.000030905783],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015253454,0.0058560893,0.6430991,0.0002982569,0.000033842294,0.000219107,0.0009734687,0.000038489856,0.00038361715,0.0013324976,0.00050334685,0.34573677],"study_design_scores_gemma":[0.01352743,0.053381383,0.87281054,0.0009784115,0.0004887518,0.00022893144,0.00023978569,0.011041874,0.001863585,0.0062445803,0.03883762,0.00035707888],"about_ca_topic_score_codex":0.000032440454,"about_ca_topic_score_gemma":0.000050218394,"teacher_disagreement_score":0.3453797,"about_ca_system_score_codex":0.00004412992,"about_ca_system_score_gemma":0.000054828313,"threshold_uncertainty_score":0.4706947},"labels":[],"label_agreement":null},{"id":"W2494387052","doi":"10.17925/usn.2010.06.02.96","title":"Environmental Risk Factors for Pediatric Multiple Sclerosis","year":2010,"lang":"en","type":"article","venue":"touchREVIEWS in Neurology","topic":"Carcinogens and Genotoxicity Assessment","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Multiple sclerosis; Medicine; Disease; Environmental health; Immunology; Pathology","score_opus":0.02081325690780442,"score_gpt":0.24309421097132322,"score_spread":0.2222809540635188,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2494387052","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99740094,0.001050646,0.00024122316,0.000074414835,0.00043631528,0.00061007106,0.00013462534,0.000007047051,0.000044738415],"genre_scores_gemma":[0.99327487,0.0051155905,0.0005664459,0.00042988505,0.00033614284,0.00013081306,0.000091928196,0.000023987255,0.000030327536],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99883133,0.00009104456,0.00028076678,0.00043340688,0.000066267836,0.00029716757],"domain_scores_gemma":[0.99934626,0.00007453687,0.0001187832,0.00038061527,0.000008715592,0.00007110598],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023062766,0.00017483898,0.00022950044,0.00005528271,0.00006997897,0.000008486249,0.00019781658,0.00019950776,0.00006854278],"category_scores_gemma":[0.00018276607,0.00015983586,0.00016540574,0.000054691624,0.000057930127,0.000002582147,0.00011075249,0.00023990756,0.000012643417],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000608128,0.00013172659,0.5389949,0.000019336443,0.000008539478,0.0000012502629,0.000022345152,0.000034916968,0.4546295,0.000011361517,0.000787448,0.0052978187],"study_design_scores_gemma":[0.0014306817,0.00087895896,0.77714133,0.0000017895134,0.000059059395,0.000012422633,0.000011972924,0.00017950151,0.05442904,0.00006230848,0.16543238,0.0003605835],"about_ca_topic_score_codex":0.000033073775,"about_ca_topic_score_gemma":0.00034778577,"teacher_disagreement_score":0.4002005,"about_ca_system_score_codex":0.0000050093104,"about_ca_system_score_gemma":0.000020625183,"threshold_uncertainty_score":0.6517917},"labels":[],"label_agreement":null},{"id":"W2799778697","doi":"10.17925/usn.2018.14.1.35","title":"Homocysteine Lowering with B Vitamins for Stroke Prevention—A History","year":2018,"lang":"en","type":"article","venue":"touchREVIEWS in Neurology","topic":"Folate and B Vitamins Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Methylcobalamin; Vitamin B12; Cyanocobalamin; Stroke (engine); B vitamins; Homocysteine; Internal medicine; Renal function; Gastroenterology; Endocrinology","score_opus":0.05588673959660658,"score_gpt":0.3377961441035223,"score_spread":0.28190940450691576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2799778697","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97714645,0.0077974745,0.0010667802,0.0015655234,0.00042437838,0.0019685652,0.000005895549,0.000061004797,0.009963951],"genre_scores_gemma":[0.97686994,0.0014603105,0.0016003669,0.0026912617,0.00064308813,0.00038528896,0.000022361519,0.000061001865,0.01626639],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99865884,0.00007698622,0.00033595233,0.0003718416,0.00015602556,0.0004003434],"domain_scores_gemma":[0.9992003,0.0000889704,0.00007558819,0.00042080216,0.00011930493,0.000095078765],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003691865,0.00015400468,0.00046647206,0.00021548377,0.00003697344,0.0000040458135,0.00013790965,0.000103920465,0.00044717776],"category_scores_gemma":[0.00015151409,0.00011698061,0.00009536465,0.00015359971,0.00021662065,0.000065229906,0.00005212575,0.00026470466,0.00011216316],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01695937,0.0040718336,0.08927514,0.006708857,0.0005791198,0.0023071952,0.0016447249,0.000012566742,0.15287206,0.0024318572,0.13141756,0.59171975],"study_design_scores_gemma":[0.003512713,0.012274987,0.011895578,0.00017711284,0.00007520516,0.00033320446,0.0000060827706,0.0002564822,0.0018674455,0.000041376505,0.96939087,0.00016896932],"about_ca_topic_score_codex":0.000022818716,"about_ca_topic_score_gemma":0.00027335738,"teacher_disagreement_score":0.8379733,"about_ca_system_score_codex":0.00008807881,"about_ca_system_score_gemma":0.00014994008,"threshold_uncertainty_score":0.48962831},"labels":[],"label_agreement":null},{"id":"W2802999705","doi":"10.17925/usn.2018.14.1.47","title":"Edaravone in Amyotrophic Lateral Sclerosis’Lessons from the Clinical Development Program and the Importance of a Strategic Clinical Trial Design","year":2018,"lang":"en","type":"article","venue":"touchREVIEWS in Neurology","topic":"Amyotrophic Lateral Sclerosis Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Mitsubishi Tanabe Pharma Corporation; Mallinckrodt Pharmaceuticals","keywords":"Edaravone; Amyotrophic lateral sclerosis; Medicine; Clinical trial; Drug development; Clinical study design; Cohort; Disease; Intensive care medicine; Oncology; Pharmacology; Internal medicine; Drug","score_opus":0.45025775534504736,"score_gpt":0.4830974873236365,"score_spread":0.03283973197858914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2802999705","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9711562,0.0028692465,0.000017256029,0.021115646,0.00035176458,0.004370748,0.0000031454654,0.000023008864,0.00009299596],"genre_scores_gemma":[0.9771484,0.012532669,0.002082619,0.0071311006,0.0005526416,0.00050164876,0.000008444945,0.000027714736,0.000014755792],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9912956,0.0044869827,0.0025437116,0.00073170464,0.00037554052,0.00056651176],"domain_scores_gemma":[0.9960711,0.002408485,0.00045731725,0.00080536667,0.00010816629,0.00014958641],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007664571,0.00026569294,0.001421362,0.000070894195,0.00008355442,0.000026821059,0.00052014616,0.00029873895,0.00014964452],"category_scores_gemma":[0.0013456444,0.0001335286,0.00019697267,0.00043798305,0.002498907,0.000050690694,0.00030587186,0.0014463649,0.00003722552],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2012847,0.0032362123,0.5484468,0.00010127191,0.00023645247,0.00020760974,0.0007027941,0.00000430578,0.000397488,0.0013052915,0.002018686,0.24205841],"study_design_scores_gemma":[0.050489012,0.0052414583,0.9363771,0.00024231711,0.000057977526,0.000018245222,0.000007839868,0.00072298315,0.000008654058,0.0015546122,0.0051354757,0.00014430167],"about_ca_topic_score_codex":0.00013604181,"about_ca_topic_score_gemma":0.00052375236,"teacher_disagreement_score":0.38793036,"about_ca_system_score_codex":0.000026172216,"about_ca_system_score_gemma":0.00043468125,"threshold_uncertainty_score":0.92073274},"labels":[],"label_agreement":null},{"id":"W2944875226","doi":"10.17925/usn.2019.15.1.18","title":"Imaging, Technology, and Parkinson’s Disease","year":2019,"lang":"en","type":"article","venue":"touchREVIEWS in Neurology","topic":"Neurological disorders and treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Movement Disorders","funders":"","keywords":"Deep brain stimulation; Medicine; Movement disorders; Dystonia; Essential tremor; Neuromodulation; Parkinson's disease; Neuroimaging; Translational research; Neurosurgery; Neurology; Clinical neuroscience; Neuroscience; Physical medicine and rehabilitation; Disease; Psychology; Psychiatry; Pathology; Internal medicine","score_opus":0.012124010692921676,"score_gpt":0.27244209693065635,"score_spread":0.26031808623773467,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2944875226","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95691264,0.018415565,0.0000021186634,0.020614073,0.000116270014,0.00076234917,0.0000023319355,0.0000612224,0.0031134193],"genre_scores_gemma":[0.97584224,0.0050358702,0.00006491275,0.018711345,0.00001520194,0.00006983177,0.000004366733,0.000014405552,0.00024182955],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989578,0.000062802224,0.00021780732,0.00043598993,0.000066043904,0.00025957133],"domain_scores_gemma":[0.9994432,0.000039790062,0.0000493632,0.00034536808,0.000012849045,0.00010944593],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007094385,0.00014967281,0.00039140045,0.00020621384,0.000017761653,0.0000046074533,0.00007571239,0.000067428504,0.00027980687],"category_scores_gemma":[0.000093965304,0.00011040725,0.000052096948,0.0002480252,0.00012376388,0.000032301552,0.000089468194,0.00025895782,0.0002543343],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017418718,0.00016481301,0.96725863,0.00006932661,0.000005023339,0.00057458447,0.0000044015105,3.9496751e-7,0.00009345268,0.0010689382,0.00056422106,0.03002204],"study_design_scores_gemma":[0.0017302698,0.00046971408,0.74134463,0.00003015688,0.000039130773,0.00007406457,0.0000016383766,0.000121599536,0.000007814018,0.007837192,0.24824905,0.00009475],"about_ca_topic_score_codex":0.0000054460234,"about_ca_topic_score_gemma":0.0000029946941,"teacher_disagreement_score":0.24768484,"about_ca_system_score_codex":0.0000058805053,"about_ca_system_score_gemma":0.000017566877,"threshold_uncertainty_score":0.4502277},"labels":[],"label_agreement":null},{"id":"W32808450","doi":"10.17925/usn.2010.06.01.36","title":"Monoamine Oxidase Type B Inhibitors in the Treatment of Early Parkinson’s Disease","year":2010,"lang":"en","type":"article","venue":"touchREVIEWS in Neurology","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Movement Disorders","funders":"National Institutes of Health; Ipsen; Teva Pharmaceutical Industries","keywords":"Medicine; Levodopa; Carbidopa; Monoamine oxidase B; Parkinson's disease; Monoamine oxidase; Disease; Selegiline; Pharmacology; Pharmacotherapy; Dopamine; Internal medicine; Enzyme","score_opus":0.025699423578684544,"score_gpt":0.2946161251388231,"score_spread":0.2689167015601386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W32808450","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99119663,0.005629027,8.626363e-7,0.0013654093,0.0003442909,0.001092364,0.000013462511,0.0000149259395,0.00034303314],"genre_scores_gemma":[0.9936413,0.004912722,0.00008984822,0.0009320097,0.00011261395,0.00021491012,0.000021819755,0.000019489806,0.000055251818],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985725,0.00020009153,0.00042750625,0.00035689946,0.00015784599,0.0002851008],"domain_scores_gemma":[0.9989861,0.00010788169,0.00011580211,0.0006079916,0.000029496237,0.00015271205],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017795917,0.00022091587,0.00051448884,0.00016855713,0.000023047927,0.000005572558,0.00013390176,0.00009073207,0.00012244341],"category_scores_gemma":[0.00010306447,0.00013556663,0.00014078758,0.00033180075,0.000080819125,0.000038304763,0.000019165753,0.00021013623,0.00005722345],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019794437,0.005461814,0.91580665,0.00012752252,0.000042643664,0.0026695714,0.000566213,0.0000032547453,0.0029292821,0.00055378396,0.00030157177,0.06955824],"study_design_scores_gemma":[0.002453759,0.0022721142,0.7624085,0.000034027413,0.00012404882,0.000029552282,0.0000043611712,0.00004879701,0.00034660214,0.00033189714,0.23185264,0.00009372348],"about_ca_topic_score_codex":0.00017424722,"about_ca_topic_score_gemma":0.00025097528,"teacher_disagreement_score":0.23155107,"about_ca_system_score_codex":0.000023539964,"about_ca_system_score_gemma":0.00008162428,"threshold_uncertainty_score":0.5528247},"labels":[],"label_agreement":null},{"id":"W4210542383","doi":"10.17925/usn.2009.05.01.75","title":"Advances in Medical Management of Cluster Headache","year":2009,"lang":"en","type":"article","venue":"touchREVIEWS in Neurology","topic":"Migraine and Headache Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovation Cluster (Canada)","funders":"","keywords":"Medicine; Cluster headache; Sumatriptan; Zolmitriptan; Methysergide; Topiramate; Triptans; Tolerability; Anesthesia; Verapamil; Migraine; Rizatriptan; Epilepsy; Internal medicine; Adverse effect; Agonist","score_opus":0.022875963400549627,"score_gpt":0.3577844737415116,"score_spread":0.334908510340962,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210542383","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.43424317,0.22326258,0.00010838516,0.093362615,0.000116610856,0.0019873497,0.0000014419817,0.00004812666,0.24686974],"genre_scores_gemma":[0.8203097,0.15583302,0.00058123283,0.022698069,0.00008709014,0.000042247146,0.0000037527786,0.000009049221,0.000435866],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99866456,0.00011854404,0.00055099465,0.00022809785,0.00019735418,0.00024042162],"domain_scores_gemma":[0.99956834,0.000069346155,0.000064478045,0.0002277561,0.000015653568,0.00005441245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047357407,0.00011677974,0.0006109083,0.0001289544,0.000009042399,7.1696246e-7,0.00010723175,0.00008605845,0.00022646578],"category_scores_gemma":[0.000100671015,0.000088693276,0.000076973534,0.00025531466,0.0000733525,0.000034446297,0.000050286977,0.00029789135,0.000018613217],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011910256,0.0014753491,0.09439506,0.003106314,0.0000395833,0.0022859313,0.0007752081,0.00001873447,0.00010853433,0.010086306,0.032693993,0.85382396],"study_design_scores_gemma":[0.0035881556,0.001590039,0.28091463,0.00086160906,0.000055527616,0.00017789319,0.00005690254,0.00017821639,0.000038715738,0.0017061037,0.7106744,0.00015783761],"about_ca_topic_score_codex":0.000014379039,"about_ca_topic_score_gemma":0.00023462325,"teacher_disagreement_score":0.8536661,"about_ca_system_score_codex":0.000009735122,"about_ca_system_score_gemma":0.000019977211,"threshold_uncertainty_score":0.3616807},"labels":[],"label_agreement":null},{"id":"W4212945886","doi":"10.17925/usn.2021.17.2.70","title":"Innovative Therapeutic Development Programme for the Treatment of Early Alzheimer's Disease: Lecanemab (BAN2401)","year":2021,"lang":"en","type":"article","venue":"touchREVIEWS in Neurology","topic":"Cholinesterase and Neurodegenerative Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Resverlogix (Canada)","funders":"National Institute of Neurological Disorders and Stroke; National Institute of General Medical Sciences; National Institute on Aging","keywords":"Disease; Alzheimer's disease; Medicine; Internal medicine","score_opus":0.12047899836111475,"score_gpt":0.36350853864702065,"score_spread":0.2430295402859059,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212945886","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8890025,0.10422005,0.0000958666,0.0041778814,0.00018767489,0.0022201564,0.00002085357,0.000019726996,0.000055308992],"genre_scores_gemma":[0.9819509,0.009254837,0.00034634027,0.0062801233,0.00017940033,0.0016798452,0.00011449686,0.00003754821,0.00015652325],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985176,0.00017560089,0.0005116064,0.00037608403,0.00012735261,0.00029178904],"domain_scores_gemma":[0.9987434,0.00036139603,0.00013101674,0.00041043837,0.00026315366,0.00009058193],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010230223,0.00021513097,0.00053386274,0.00006977421,0.00005734682,0.000008931979,0.00008852661,0.00004443051,0.000059347145],"category_scores_gemma":[0.00010977287,0.00013265472,0.00015163008,0.00045241698,0.00010581747,0.000028360359,0.000023153392,0.00008838223,0.0000069941802],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031122796,0.004419724,0.12280942,0.0003520601,0.0006323723,0.0005286824,0.0014937654,0.000019721714,0.0034593127,0.0011708057,0.000428606,0.8615733],"study_design_scores_gemma":[0.0043842187,0.0027523676,0.4286078,0.000105354746,0.00073194114,0.000056095538,0.000030389163,0.00009214684,0.026015887,0.000116672105,0.5368677,0.00023943809],"about_ca_topic_score_codex":0.000007750767,"about_ca_topic_score_gemma":0.000039911054,"teacher_disagreement_score":0.8613338,"about_ca_system_score_codex":0.000021926413,"about_ca_system_score_gemma":0.00047775276,"threshold_uncertainty_score":0.54095024},"labels":[],"label_agreement":null},{"id":"W4246577497","doi":"10.17925/usn.2013.09.01.35","title":"Symptomatic Treatment in Multiple Sclerosis","year":2013,"lang":"en","type":"article","venue":"touchREVIEWS in Neurology","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Medicine; Multiple sclerosis; Spasticity; Quality of life (healthcare); Depression (economics); Disease; Physical medicine and rehabilitation; Balance (ability); Gait; Sexual dysfunction; Physical therapy; Psychiatry; Internal medicine","score_opus":0.12730641820576927,"score_gpt":0.327353612265473,"score_spread":0.20004719405970373,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4246577497","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9857561,0.0038582934,0.0000035607566,0.005546771,0.00010122991,0.0029530695,0.0000023398588,0.000048343794,0.0017302725],"genre_scores_gemma":[0.9750376,0.020464536,0.00043849245,0.0017844235,0.00006744485,0.0020158603,0.0000066948464,0.000026862697,0.00015808525],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977409,0.0003708595,0.00064428506,0.00045025573,0.00019464435,0.0005990393],"domain_scores_gemma":[0.99866647,0.0005451344,0.000079229714,0.0005231408,0.000047862435,0.000138162],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00027284186,0.00024563516,0.0008879853,0.00032774787,0.00003724628,0.000012061177,0.00014622408,0.00010707157,0.00071897265],"category_scores_gemma":[0.0009774474,0.00017932174,0.00012214523,0.00041872697,0.00014708903,0.000086726985,0.00010884572,0.00028807265,0.0009754654],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010262157,0.0008283336,0.76087964,0.00030154956,0.00003446085,0.00007479555,0.00043099586,0.000022068016,0.008596973,0.00002071446,0.002200915,0.22650693],"study_design_scores_gemma":[0.0035030774,0.0008479192,0.9826873,0.00021110298,0.000014758843,0.000020187226,0.000018142136,0.002582583,0.00029079962,0.00004616443,0.009649469,0.0001285008],"about_ca_topic_score_codex":0.0013576524,"about_ca_topic_score_gemma":0.0010164273,"teacher_disagreement_score":0.22637843,"about_ca_system_score_codex":0.00013411784,"about_ca_system_score_gemma":0.000049541704,"threshold_uncertainty_score":0.9998024},"labels":[],"label_agreement":null},{"id":"W4247336648","doi":"10.17925/usn.2011.07.01.41","title":"Stroke Rehabilitation—An Overview of Existing Guidelines and Standards of Care","year":2011,"lang":"en","type":"article","venue":"touchREVIEWS in Neurology","topic":"Stroke Rehabilitation and Recovery","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Rehabilitation; Guideline; Stroke (engine); Best evidence; Health care; Clinical Practice; Alternative medicine; MEDLINE; Physical therapy; Intensive care medicine; Pathology","score_opus":0.20343810368851664,"score_gpt":0.43136387943434895,"score_spread":0.2279257757458323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4247336648","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93724924,0.057022102,0.000027375509,0.00035642966,0.00017944202,0.0005503944,0.000038973205,0.000013638003,0.004562385],"genre_scores_gemma":[0.95921427,0.017134855,0.022620482,0.0008407057,0.00006790374,0.000039870505,0.000008137848,0.000024033363,0.000049752718],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99833095,0.0002539623,0.000853311,0.00022693074,0.00021315367,0.000121716475],"domain_scores_gemma":[0.9983657,0.00033978486,0.00022434766,0.00030506827,0.00070864975,0.000056445864],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00081785803,0.00010957276,0.0006630833,0.00017993382,0.000012403462,9.963524e-7,0.00006502294,0.000086087144,0.0001646048],"category_scores_gemma":[0.0036894397,0.000087350425,0.0001114915,0.00014663774,0.00020114543,0.000054367792,0.000034310622,0.00012335631,9.638029e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011010795,0.0003402607,0.7320003,0.010059023,0.000039143983,0.000017764962,0.008537009,0.000011529294,0.0028896185,0.0064125517,0.00072270655,0.23786901],"study_design_scores_gemma":[0.0033962002,0.013496635,0.8515134,0.001750761,0.00018669268,0.00009520585,0.0016904159,0.00014893076,0.0010848136,0.00120812,0.12516515,0.0002636788],"about_ca_topic_score_codex":0.000083173174,"about_ca_topic_score_gemma":0.00007937205,"teacher_disagreement_score":0.23760533,"about_ca_system_score_codex":0.000019724186,"about_ca_system_score_gemma":0.00011770798,"threshold_uncertainty_score":0.44168705},"labels":[],"label_agreement":null},{"id":"W4249026402","doi":"10.17925/usn.2011.07.02.84","title":"Chronic Cerebrospinal Venous Insufficiency in Multiple Sclerosis—A Medical, Sociological, and Media Controversy","year":2011,"lang":"en","type":"article","venue":"touchREVIEWS in Neurology","topic":"Cerebral Venous Sinus Thrombosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Multiple sclerosis; Clinical trial; Skepticism; Intensive care medicine; Internal medicine; Psychiatry","score_opus":0.10343163843929372,"score_gpt":0.27935728291910067,"score_spread":0.17592564447980696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4249026402","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97981095,0.015262309,0.000014655092,0.0017068745,0.0003244132,0.0009258755,0.000005581974,0.000066468485,0.0018828599],"genre_scores_gemma":[0.9738633,0.021252207,0.0002696166,0.004255529,0.00021695897,0.00009590695,0.000008964531,0.000031490898,0.0000060155226],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970177,0.00039458327,0.0008591069,0.00068932475,0.0003053577,0.0007339505],"domain_scores_gemma":[0.9986256,0.0004411306,0.00018277174,0.00043628406,0.00004061975,0.00027363046],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00081230636,0.00030706346,0.001236368,0.00023024969,0.00006962954,0.0000066858047,0.0002965867,0.00046550253,0.0016394128],"category_scores_gemma":[0.002061442,0.00025273763,0.0001164333,0.00037088702,0.00079554995,0.000075975724,0.00021175102,0.0010148606,0.00013068698],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014606138,0.011866376,0.8282564,0.0011298892,0.000086523614,0.002051075,0.005675472,0.0000056618414,0.005398922,0.0039134985,0.0020683887,0.13808714],"study_design_scores_gemma":[0.005183892,0.00808585,0.98065275,0.0003229028,0.000055018863,0.00035945067,0.000038104194,0.00033516102,0.00009148211,0.0005050651,0.00408807,0.00028223728],"about_ca_topic_score_codex":0.0005770294,"about_ca_topic_score_gemma":0.0016123584,"teacher_disagreement_score":0.15239634,"about_ca_system_score_codex":0.00013259366,"about_ca_system_score_gemma":0.00027494275,"threshold_uncertainty_score":0.9999925},"labels":[],"label_agreement":null},{"id":"W4255101771","doi":"10.17925/usn.2012.08.01.12","title":"Deep Brain Stimulation for Parkinson’s Disease—A Review","year":2012,"lang":"en","type":"article","venue":"touchREVIEWS in Neurology","topic":"Neurological disorders and treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Movement Disorders; University of British Columbia","funders":"","keywords":"Deep brain stimulation; Medicine; Dyskinesia; Parkinson's disease; Disease; Intervention (counseling); Motor symptoms; Medical therapy; Physical medicine and rehabilitation; Refractory (planetary science); Intensive care medicine; Physical therapy; Neuroscience; Psychiatry; Surgery; Psychology; Pathology","score_opus":0.049194210209526065,"score_gpt":0.344750848154001,"score_spread":0.2955566379444749,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4255101771","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1708512,0.73972845,0.0010136252,0.076614775,0.00074953336,0.008745895,0.000016420167,0.00013612505,0.002143953],"genre_scores_gemma":[0.7098224,0.08109765,0.00055631285,0.2069415,0.00022434781,0.0010365755,0.000115792216,0.00004021254,0.00016520498],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985882,0.00020197261,0.00040170693,0.0003010315,0.00010166371,0.00040541624],"domain_scores_gemma":[0.99907535,0.0002798153,0.00009989018,0.00031684162,0.000022670627,0.00020540631],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030489295,0.0001780448,0.0005521222,0.00005691326,0.000033175238,0.0000026397122,0.00007445714,0.00007168793,0.0002935368],"category_scores_gemma":[0.0008075319,0.00013094905,0.00017454552,0.00015726656,0.00003840244,0.000066342946,0.00003192678,0.00015453881,0.00010154422],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011266874,0.0016866602,0.75285524,0.0043519605,0.00003740286,0.00010808826,0.000037176287,0.000017635291,0.000048056765,0.0014478123,0.03976858,0.19851467],"study_design_scores_gemma":[0.0015430821,0.00060272403,0.42328256,0.00021599884,0.00017079792,0.000014896403,3.2554541e-7,0.00036013362,0.0000020301395,0.0013459933,0.57234716,0.00011430796],"about_ca_topic_score_codex":0.0000025255522,"about_ca_topic_score_gemma":0.000004747479,"teacher_disagreement_score":0.65863085,"about_ca_system_score_codex":0.000013907886,"about_ca_system_score_gemma":0.0000165438,"threshold_uncertainty_score":0.53399473},"labels":[],"label_agreement":null}]}